BioPharm International speaks with a CMO to find out how it is coping with capacity challenges, regulatory authority scrutiny, supply chain reliability, and new requests from clients to incorporate continuous manufacturing into processing lines.
Demand for biologic drug processing is placing pressure on contract manufacturing organizations to meet capacity demands in a timely manner. Christoph Winterhalter, senior vice-president of business development at Rentschler Biotechnologie GmbH, discusses the ways the company is prepared to handle new challenges related to client requests and heightened scrutiny from regulatory authorities.
Read this articlefrom BioPharm International’s 2017 Outsourcing Resources eBook.
View other articles in the
2017 Outsourcing Resources eBook.
Novel Modalities Spur Shift in Outsourcing Processes and Partnerships
May 8th 2025While a one-stop shop still has its advantages, sponsor companies and CDMOs are starting to see each other not as transactional relationships, but true partners with a common goal of getting drugs to patients faster.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.